indazoles has been researched along with benzyloxycarbonylleucyl-leucyl-leucine aldehyde in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cadenas, E; Lam, PY | 1 |
| Alcantara, SL; Brzozowski, MJ; Iravani, MM; Jenner, P; Rose, S | 1 |
| Bertoni, F; Bujisic, B; Chelbi, S; De Gassart, A; Demaria, O; Gilliet, M; Martinon, F; Tallant, R; Zaffalon, L | 1 |
| Chen, X; Yang, C; Zhang, J; Zhou, F | 1 |
4 other study(ies) available for indazoles and benzyloxycarbonylleucyl-leucyl-leucine aldehyde
| Article | Year |
|---|---|
Compromised proteasome degradation elevates neuronal nitric oxide synthase levels and induces apoptotic cell death.
Topics: Animals; Apoptosis; Caspase 3; Caspase 9; Cell Survival; Cysteine Proteinase Inhibitors; Indazoles; JNK Mitogen-Activated Protein Kinases; Leupeptins; Neurons; Nitric Oxide Synthase; Nitric Oxide Synthase Type I; PC12 Cells; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Rats; Reactive Nitrogen Species; Signal Transduction | 2008 |
The effect of nNOS inhibitors on toxin-induced cell death in dopaminergic cell lines depends on the extent of enzyme expression.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amidines; Animals; Asparagine; Caspase 3; Cell Death; Cell Line, Tumor; Citrulline; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Indazoles; L-Lactate Dehydrogenase; Leupeptins; Mice; Neuroblastoma; Neurotoxins; Nitric Oxide Synthase Type I; Thiophenes; Transfection; Tritium; Tyrosine 3-Monooxygenase; Vesicular Monoamine Transport Proteins | 2011 |
Impairment of both IRE1 expression and XBP1 activation is a hallmark of GCB DLBCL and contributes to tumor growth.
Topics: Animals; B-Lymphocytes; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Endoribonucleases; Enhancer of Zeste Homolog 2 Protein; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Germinal Center; Histones; Humans; Indazoles; Leupeptins; Lymphoma, Large B-Cell, Diffuse; Mice; Mice, 129 Strain; Plasma Cells; Promoter Regions, Genetic; Protein Serine-Threonine Kinases; Pyridones; RNA, Messenger; Signal Transduction; X-Box Binding Protein 1; Xenograft Model Antitumor Assays | 2017 |
PDK1 inhibitor GSK2334470 synergizes with proteasome inhibitor MG‑132 in multiple myeloma cells by inhibiting full AKT activity and increasing nuclear accumulation of the PTEN protein.
Topics: Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Cell Survival; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Leupeptins; Multiple Myeloma; Phosphorylation; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyrimidines; TOR Serine-Threonine Kinases | 2018 |